🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 5 of 18

  1. US 11826386

    Compositions and methods for treating cancer

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11820826

    Anti-NPR1 antibodies and uses thereof

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11820815

    Human antibodies to human delta like ligand 4

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11820982

    Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11814428

    Anti-PTCRA antibody-drug conjugates and uses thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11806398

    Citrate buffered VEGF antagonist formulations

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11787867

    Anti-GITR antibodies and uses thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11786606

    Site-specific quantitation of drug conjugations

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11786603

    Optimized transglutaminase site-specific antibody conjugation

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11778995

    Genetically modified non-human animals and methods of use thereof

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11780907

    Human antibodies to influenza hemagglutinin

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11779633

    Glucagon-like peptide 1 receptor agonists and uses thereof

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11771762

    Anti-ErbB3 antibodies and uses thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11773393

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11773156

    Anti-hemagglutinin antibodies and methods of use thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11771743

    Methods for preventing or treating allergy by administering an IL-4R antagonist

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11769597

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11767526

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11767358

    Human antibodies to Bet v 1 and methods of use thereof

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11766032

    Genetically modified non-human animals expressing human EPO

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11760775

    Steroids and protein-conjugates thereof

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11759476

    Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11753628

    HSD17B13 variants and uses thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11752214

    Protein-antiviral compound conjugates

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11752197

    Macrophage stimulating 1 receptor (MST1R) variants and uses thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11732030

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11730793

    Sustained release formulations using non-aqueous emulsions

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11732025

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11730794

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11730150

    Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11725034

    IL2 agonists and methods of use thereof

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11713461

    Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11713922

    Target residual moisture content for lyophilized drug product

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11708416

    Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11708407

    Antigen binding molecule formats

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11707506

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11708415

    Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11701427

    Diels-alder conjugation methods

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11696572

    Non-human animals comprising a humanized ASGR1 locus

    Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11692032

    Anti-LAG3 antibodies and uses thereof

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11684050

    Non-human animals having a humanized programmed cell death 1 gene

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11674968

    Methods for identifying free thiols in proteins

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11674177

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11673967

    Stabilized formulations containing anti-PCSK9 antibodies

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11673930

    IL10 agonists and methods of use thereof

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11667701

    Anti-PfRH5 antibodies and antigen-binding fragments thereof

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.